Exelixis Slashes Staff Again, Focuses All Internal Development on XL184
As many as 65% of the oncology biotech's employees could be shown the door as the company ceases research on all but one drug candidate.
As many as 65% of the oncology biotech's employees could be shown the door as the company ceases research on all but one drug candidate.